GlassScriptPhysician profile
Michael W Sperling
NPI 1326579392
$4,245.40
in general payments reported to CMS, 2019-2025
34 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $206 · 2021: $520 · 2022: $772 · 2023: $731 · 2024: $932 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.47 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $679.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $551.51 | 2020-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $504.37 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $321.55 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $298.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.27 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $226.58 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.74 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $125.14 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $106.78 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $105.54 | 2021-2025 | |
| Lilly USA, LLC | $102.56 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $94.40 | 2022-2025 | |
| Abbott Laboratories | $89.77 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $81.06 | 2023-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $75.11 | 2022-2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $73.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.23 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $38.37 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $37.28 | 2022-2023 | |
| Nevro Corp. | $19.37 | 2023 | Senza |
| Esperion Therapeutics, INC. | $18.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.95 | 2025 | Jardiance |
| Seqirus USA INC | $18.91 | 2025 | Fluad, Flucelvax |
| Otsuka America Pharmaceutical, INC. | $18.26 | 2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $16.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.43 | 2021 | |
| Hologic Sales and Service, LLC | $16.21 | 2023 | Aptima, Thinprep 2000 Processor |
| Mylan Specialty L.P. | $15.67 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.33 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $14.23 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.72 | 2025 | Voquezna |
| Eisai INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sperling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.